Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding scientists in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

As the leader of a cross-functional Cancer Pharmacology team, you will report into Executive Director and Head of Cancer Pharmacology in Translational Research:

• Be a critical contributor and provide strong strategic and technical leadership in translation research group and multi-disciplinary research and development project teams with a focus on preclinical modeling of combinations and resistance with an indication lens.
• Strategic involvement in external partnering and business development efforts. Coordinate internal efforts and external contract research organization for various pharmacology programs.
• Manage a team of scientists across different projects in a matrix environment, have the ability to serve as a functional rep in key project teams.
• Manage and analyze experimental data and present results at internal meetings and scientific conferences.
• Develop high-quality protocols and outputs and maintain detailed documentation of procedures and data to comply with internal standard operating procedures and other quality criteria, where necessary.

Required Experience, Skills, and Education:

• Ph.D. degree in pharmacology, oncology, cell biology or a related discipline, with 2-5 years of post-doctoral and at least 8-10 years of relevant industry experience in cancer drug discovery and development.
• Strategic thinker with proven leadership skills, prior project team leadership roles would be an advantage.
• Deep expertise in cancer pharmacology and oncogenic signaling pathways is important.

• Rigorous, quantitative and detail-oriented experimentalist.
• Strong track record of scientific productivity as evidenced by high-quality, impactful publications.
• Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important.
• Experience working with external collaborators on both preclinical animal studies and ex vivo PD assays is preferred.
• Excellent written and verbal communication skills.
• Thrives in a collaborative team setting and is driven by a desire to be innovative in a high energy, small company environment.

The expected salary range for this role is $235,000 to $281,000. An individual’s position within the range may be influenced by multiple factors, including skills and experience in role, overall performance, individual impact and contributions, tenure, and market dynamics. Base salary is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.